NR1H4 and cholangiocarcinoma: Critically, ​​heterogeneous FXR expression across CCA subtypes directs subtype-specific therapeutic strategies.​​ ​​In chemotherapy-resistant iCCA models​​, the ​​combination of FXR agonists (e.g., GW4064, CDCA)​​ with standard chemotherapy (cisplatin/gemcitabine) ​​potentiates anti-proliferative and pro-apoptotic responses​​ (129).